4D Molecular Therapeutics

Develops gene therapies for genetic diseases

Emeryville, California, United States

Visit Website View Jobs

About 4D Molecular Therapeutics

4D Molecular Therapeutics develops gene therapies aimed at treating serious genetic diseases by delivering specific genetic material to patients' cells. The company utilizes a unique technology called Therapeutic Vector Evolution to create adeno-associated virus (AAV) vectors, which act as delivery vehicles for therapeutic genes targeting affected cells in the body. Unlike many competitors, 4DMT focuses on precision medicine for genetic disorders, including cystic fibrosis, and operates in the specialized biopharmaceutical market. Their goal is to advance gene therapies through rigorous research and clinical trials, ultimately commercializing effective treatments either directly or through partnerships with larger pharmaceutical companies.

Emeryville, CaliforniaHeadquarters
2013Year Founded
$170.2MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Risks

Public stock offering may dilute existing shareholders' equity, causing dissatisfaction.
Analysts cutting estimates suggest potential financial instability or unmet expectations.
Reliance on partnerships like Astellas poses risk if outcomes don't meet expectations.

Differentiation

4DMT uses proprietary Therapeutic Vector Evolution for advanced AAV vector creation.
Their focus is on gene therapies for serious genetic diseases like cystic fibrosis.
4DMT's R100 vector technology efficiently targets retinal cells for eye disease treatment.

Upsides

4DMT secured a $962 million deal with Astellas for their vector technology.
Positive interim data from 4D-710 trials show promise for cystic fibrosis treatment.
Series C financing raised $75 million, boosting research and development capabilities.

Funding

Total raised$170.23 M
Latest valuation$375.00 M
StageIPO
POST IPO EQUITY
1/31/2024
$300
SERIES C
5/31/2020
$75
$375.00 M
SERIES B
8/31/2018
$90
$450.00 M
SERIES A
8/31/2017
$3
$15.00 M
EARLY VC
7/31/2015
$7
$35.00 M